Trial Profile
Safety and pharmacokinetics of idelalisib in subjects with renal impairments and healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2016
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Myelofibrosis; Non-Hodgkin's lymphoma; Pancreatic cancer; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
- 11 May 2016 New trial record